(±) -Ibipinabant

(±) -Ibipinabant ((±) -SLV319) is the racemate of SLV319. (±) -Ibipinabant ((±) -SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.

Product Specifications

CAS Number

[362519-49-1]

Product Name Alternative

(±) -SLV319; (±) -BMS-646256

UNSPSC

12352005

Target

Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/__plusmn__-SLV319.html

Purity

99.30

Solubility

DMSO : ≥ 31 mg/mL

Smiles

C/N=C(N1N=C(C2=CC=C(Cl)C=C2)C(C3=CC=CC=C3)C1)\NS(=O)(C4=CC=C(Cl)C=C4)=O

Molecular Formula

C23H20Cl2N4O2S

Molecular Weight

487.40

References & Citations

[1]Chorvat RJ, et al. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct 1;22 (19) :6173-80.|[2]Lange JH, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB (1) cannabinoid receptor antagonists. J Med Chem. 2004 Jan 29;47 (3) :627-43.|[3]Rohrbach K, et al. Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes Metab. 2012 Jun;14 (6) :555-64.